Comparison of the efficacy of fenofibrate and acipimox on plasma lipoprotein subclasses distribution in the Chinese population with Type 2 diabetes mellitus and hypertriglyceridemia

References

• Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators: efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366, 1267–1278 (2005).
   Google Scholar
• Busik JV, Esselman WJ, Reid GE. Examining the role of lipid mediators in diabetic retinopathy. Clin. Lipidol. 7(6), 661–675 (2012).
   Google Scholar
• Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 26(8), 2392–2399 (2003).
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79(1), 8–15 (1989).
   Google Scholar
• Ansquer JC, Aubonnet P, Foucher C, Le Malicot K. Fibrates and microvascular complications in diabetes – insight from the FIELD study. Curr. Pharm. Des. 15(5), 537–552 (2009).
   Google Scholar
• Koev D, Zlateva S, Susic M et al. Improvement of lipoprotein lipid composition in Type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial. Diabetes Care 16(9), 1285–1290 (1993).
   Google Scholar
• Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann. Intern. Med. 118(7), 529–539 (1993).
   Google Scholar
• Nilsson PM. ACCORD and risk-factor control in Type 2 diabetes. N. Engl. J. Med. 362(17), 1628–1630 (2010).
   Google Scholar
• Harchaoui KE, Arsenault BJ, Franssen R et al. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 150(2), 84–93 (2009).
   Google Scholar
• Singh K, Chander R, Kapoor NK. High density lipoprotein subclasses inhibit low density lipoprotein oxidation. Indian J. Biochem. Biophys. 34(3), 313–318 (1997).
   Google Scholar
• Ansell BJ. The two faces of the ‘good’ cholesterol. Cleve. Clin. J. Med. 74 (10), 697–700 (2007).
   Google Scholar
• Hiukka A, Leinonen E, Jauhiainen M et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with Type 2 diabetes mellitus. Diabetologia 50(10), 2067–2075 (2007).
   Google Scholar
• Leus FR, Leerink CB, Prins J, van Rijn HJ. Influence of apolipoprotein(a) phenotype on lipoprotein(a) quantification: evaluation of three methods. Clin. Biochem. 27(6), 449–455 (1994).
   Google Scholar
• Tian L, Fu MD. The relationship between high density lipoprotein subclass profile and plasma lipids concentrations. Lipids Health Dis. 9, 118–127 (2010).
   Google Scholar
• lamarche B, Desroches S, Jenkins DJ et al. Combined effects of a dietary portfolio of plant sterosl, vegetable protein, viscous fibre and almonds on LDL particle size. Br. J. Nutr. 92(4), 657–663 (2004).
   Google Scholar
• Asztalos BF. High-density lipoprotein particles, coronary heart disease, and niacin. J. Clin. Lipidol. 4(5), 405–410 (2010).
   Google Scholar
• Kashyap ML. Mechanistic studies of high-density lipoproteins. Am. J. Cardiol. 82(12A), 42U–48U (1998).
   Google Scholar
• Kawashiri MA, KobayashimJ, Noharam A et al. Impact of bezafirate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. Clin. Chim. Acta 412(11–12), 1068–1075 (2011).
   Google Scholar
• Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J. Lipid. Res. 49(12), 2641–2647 (2008).
   Google Scholar
• Watts GF, Barrett PH, Ji J et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52(3), 803–811 (2003).
   Google Scholar
• Kim DM, Park JR. The addition of acipimox in patients with Type 2 diabetes with triglyceride level over 150 mg/dl in spite of fenofibrate therapy. Endocrine Abstr. 26, P682 (2011).
   Google Scholar
• Santomauro AT, Boden G, Silva ME et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48(9), 1836–1841 (1999).
   Google Scholar
• Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol. 22(3), 176–185 (2011).
   Google Scholar
• Albers JJ, Vuletic S, Cheung MC. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim. Biophys. Acta 1821(3), 345–357 (2012).
   Google Scholar
• Ikewaki K, Tohyama J, Nakata Y et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. Atheroscler. Thromb. 11(5), 278–285 (2004).
   Google Scholar
• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210(2), 353–361 (2010).
   Google Scholar
• Cromwell WC, Otvos JD, Keyes MJ et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. J. Clin. Lipidol. 1(6), 583–592 (2007).
   Google Scholar
• Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem. Soc. Trans. 31(Pt 5), 1066–1069 (2003).
   Google Scholar
• Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J, Després JP. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162(2), 363–371 (2002).
   Google Scholar
• Vakkilainen J, Steiner G, Ansquer J, Aubin F, Rattier S, Foucher C. On behalf of the DAIS Group: relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107(13), 1733–1737 (2003).
   Google Scholar
• Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr. Opin. Lipidol. 17(5), 502–509 (2006).
   Google Scholar
• Daub K, Seizer P, Stellos K et al. Oxidized LDL-activated platelets induce vascular inflammation. Semin. Thromb. Hemost. 36(2), 146–156 (2010).
   Google Scholar
• Staels B, Koenig W, Habib A et al. Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature 393(6687), 790–793 (1998).
   Google Scholar
• Dong Y, Steffen BT, Cao J et al. Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. Atherosclerosis 214(2), 422–425 (2011).
   Google Scholar
• Tkác I, MolcányiováA, Javorský M, Kozárová M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol. Res. 53(3), 261–264 (2006).
   Google Scholar
• Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M. Effect of fenofibrate therapy on paraoxonase-1 status in patients with low HDL-C levels. Atherosclerosis 196(1), 122–128 (2008).
   Google Scholar